XM does not provide services to residents of the United States of America.
A
A

Amgen

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

A closer look at U.S. drug pricing risks

LIVE MARKETS-A closer look at U.S. drug pricing risks STOXX 600 up 0.8% Paris, Milan bourses outperform Fed rate cut bets support mood Wall St futures broadly unchanged Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com A CLOSER LOOK AT U.S.
A
A
E
N
U
E
F
I
U
G

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Baker Hughes Co BKR.OQ +4.8% Diamondback Energy Inc FANG.OQ +4.2% Amgen Inc AMGN.OQ +2.9% MongoDB Inc MDB.OQ +2.7% Mondelez International Inc MDLZ.OQ +2.6% Bottom Performers Percent Change Dexcom Inc DXCM.OQ -5.5% NVIDIA Corp NVDA.OQ -5.4% Arm Holdings PLC ARM.OQ -5.1% Marvell Technology Inc MRVL.OQ -4.7% Qualcomm Inc QCOM.OQ -4.4% The Nasdaq 100 .NDX lost 157.25 points, or 0.80%,
A
M
M
N
Q
U
D
D

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Baker Hughes Co BKR.OQ +3.4% Moderna Inc MRNA.OQ +2.8% Diamondback Energy Inc FANG.OQ +2.7% Mondelez International Inc MDLZ.OQ +2.4% Amgen Inc AMGN.OQ +2.2% Bottom Performers Percent Change Arm Holdings PLC ARM.OQ -4.7% NVIDIA Corp NVDA.OQ -4.6% Dexcom Inc DXCM.OQ -3.8% Qualcomm Inc QCOM.OQ -3.6% Marvell Technology Inc MRVL.OQ -3.5% The Nasdaq 100 .NDX lost 59.24 points, or 0.30%,
A
M
M
N
Q
U
D
D

US FDA approves Roche's drug for a chronic blood disorder (June 21)

CORRECTED-UPDATE 1-US FDA approves Roche's drug for a chronic blood disorder (June 21) Removes dated comment from chief medical officer in paragraph 6 of June 21 story June 21 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S drug for a chronic blood disorder, the Swiss drugmaker said. The drug crovalimab, branded as PiaSky, is a monthly under-the-skin or intravenous treatment for paroxysmal nocturnal hemoglobinuria (PNH).
A
A
R

FDA Approves Blincyto® (Blinatumomab) In Cd19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All) In The Consolidation Phase

BRIEF-FDA Approves Blincyto® (Blinatumomab) In Cd19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (B-All) In The Consolidation Phase Amgen Inc AMGN.O : FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSO
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.